Group Haselbach

Ubiquitin chain recognition and editing by the human 26S proteasome

Group Leader, Associated Member

David Haselbach

David Haselbach finished his PhD in Biophysics at the MPI for Biophysical Chemistry. After a postdoctoral stay in the same institute he became Fellow for electron microscopy at the IMP in Vienna in 2017 and became Group Leader there in 2020.

Projects within consortium

Proteasomal degradation serves as key event in the regulation of a plethora of cellular processes. While the general mechanism of proteasomal degradation is well established, key events such as the ubiquitin chain binding and processing as well as the product release are not. The Haselbach lab seeks to address these questions with modern cryo EM and biophysical methods.

Cell division and differentiation depend on the proteasomal degradation of regulating proteins like securin or myc. However, how the proteasome recognizes and distinguishes substrates is still largely unknown. Prerequisite for degradation of a target is its posttranslational modification with a ubiquitin chain. However, ubiquitin is a versatile signal. Summarized as the ubiquitin code, thousands of diverse polyubiquitin chain topologies can be formed with different lengths and linkages. However, how the proteasome selectively distinguishes between these topologies is unclear, as the early substrate-binding and initiation steps have previously been invisible to conventional approaches. This is due to the efficient rate of catalysis by the proteasome and additional editing of ubiquitin chains by proteasome associated factors. Using innovative approaches, including time-resolved cryo-electron microscopy (trEM) sample preparation, deep learning based image processing to extract thermodynamic insights, in-situ cryo EM and single-molecule techniques we will examine a systematic set of polyubiquitin chains. We will employ these approaches first to apo-proteasome complexes but will later extend to proteasomes that contain ubiquitin chain editing enzymes as they would be found in the cell.

 

On a broader perspective the Haselbach lab is interested in the proteasomes regulation and adaptation in stress and disease states.

Change of the conformational landscape of the proteasome upon inhibitor binding. Energy landscapes with and without the drug Oprozomib are depicted. Without Oprozomib, the energy landscape is rather broad and flat which allows proteasomes to sample a wide range of conformations without facing a significant energy barrier. In contrast, upon drug binding, well-separated minima can be observed next to a significant energy barrier (red) that restricts the conformational space that can be sampled by the proteasome. A 3.8 Ångstrom resolution structure was determined from particles belonging to this proteasome conformation in a local energy minimum (dark blue). A graphical representation of the movement modes is displayed below.

Project members

Targeted Protein Degradation related publications by Group Haselbach

  • 2020 Moyamoya disease factor RNF213 is a giant E3 ligase with a dynein-like core and a distinct ubiquitin-transfer mechanism eLife Ahel J, Lehner A, Vogel A, Schleiffer A, Meinhart A, Haselbach D, Clausen T Go to publication →
  • 2020 Quantifying the heterogeneity of macromolecular machines by mass photometry Nature Communications Sonn-Segev A, Belacic K, Bodrug T, Young G, VanDerLindern R, Schulman BA, Schimpf J, Friedrich T, Dip PV, Schwartz TU, Bauer B, Peters JM, Struwe WB, Benesch JLP, Brown NG#, Haselbach D#, Kukura P# (#co-corresponding authors) Go to publication →
  • 2020 The linear ubiquitin chain assembly complex generates heterotypic ubiquitin chains bioRxiv Rodriguez Carvajal A, Gomez Diaz C, Vogel A, Sonn-Segev A, Schodl K, Deszcz L, Orban-Nemeth Z, Sakamoto S, Mechtler K, Kukura P, Clausen T, Haselbach D, Ikeda F Go to publication →
  • 2019 Protein engineering of a ubiquitin-variant inhibitor of APC/C identifies a cryptic K48 ubiquitin chain binding site Proc. Natl. Acad. Sci. USA Watson ER, Grace CRR, Zhang W, Miller DJ, Davidson IF, Prabu JR, Yu S, Bolhuis DL, Kulko ET, Vollrath R, Haselbach D, Stark H, Peters JM, Brown NG, Sidhu SS, Schulman BA Go to publication →
  • 2017 Long-range allosteric regulation of the human 26S proteasome by 20S proteasome-targeting cancer drugs Nat. Commun. Haselbach D , Schrader J, Lambrecht F, Henneberg F, Chari A, Stark H Go to publication →
  • 2016 Cryo-EM of Mitotic Checkpoint Complex-Bound APC/C Reveals Reciprocal and Conformational Regulation of Ubiquitin Ligation Mol. Cell Yamaguchi M, VanderLinden R, Weissmann F, Qiao R, Dube P, Brown NG, Haselbach D, Zhang W, Sidhu SS, Peters JM, Stark H, Schulman BA Go to publication →
  • 2016 Dual RING E3 Architectures Regulate Multiubiquitination and Ubiquitin Chain Elongation by APC/C Cell Brown NG, VanderLinden R, Watson ER, Weissmann F, Ordureau Am Wu KP, Zhang W, Yu S, Mercedi PY, Harrison JS, Davidson IF, Qiao R, Lu Y, Dube P, Brunner MR, Grace CR, Miller DJ, Haselbach D, Jarvis MA, Yamaguchi M, Yanisheski D, Petzold G, Sidhu SS, Kuhlmann B, Kirschner MW, Harper JW, Peters JM, Stark H, Schulman BA Go to publication →
  • 2016 Mechanism of APC/CCDC20 activation by mitotic phosphorylation Proc. Natl. Acad. Sci. USA Qiao R, Weissmann F, Yamaguchi M, Brown NG, VanderLinden R, Imre R, Jarvis MA, Brunner MR, Davidson IF, Litos G, Haselbach D , Mechtler K, Stark H, Schulman BA, Peters JM Go to publication →
  • 2015 ProteoPlex: stability optimization of macromolecular complexes by sparse-matrix screening of chemical space Nat. Methods Chari A*, Haselbach D *, Kirves JM*, Ohmer J, Paknia E, Fischer N, Ganichkin O,Möller V, Frye JJ, Petzold G, Jarvis M, Tietzel M, Grimm C, Peters JM, Schulman BA, Tittmann K, Markl J, Fischer U, Stark H. (*equal contribution) Go to publication →